2-[2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl]quinoline | 1445746-16-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-[2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl]quinoline
• 英文别名: 2-[2-(5,8-Dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethenyl]quinoline
• CAS: 1445746-16-6
• 化学式: C₁₈H₁₅N₅
• 分子量: 301.351
• InChiKey: NYPZICQBBLSIHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  56
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Campbell John Emmerson

  公开号：US20130158003A1

  公开（公告）日：2013-06-20

  Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

  本文提供了杂环芳基化合物、其合成方法、包含该化合物的药物组合物以及使用该化合物的方法。在一种实施例中，本文提供的化合物可用于治疗、预防和/或管理各种疾病，例如中枢神经系统疾病和代谢性疾病，包括但不限于神经系统疾病、精神病、精神分裂症、肥胖症和糖尿病。
• Heteroaryl Compounds and Methods of Use Thereof
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US20150166571A1

  公开（公告）日：2015-06-18

  Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

  本文提供了杂环芳基化合物、它们的合成方法、包含这些化合物的药物组合物以及它们的使用方法。在一种实施方式中，本文提供的化合物可用于治疗、预防和/或管理各种疾病，例如中枢神经系统疾病和代谢性疾病，包括但不限于神经系统疾病、精神病、精神分裂症、肥胖症和糖尿病等。
• Quinoline derivatives as PDE10A enzyme inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20150376186A1

  公开（公告）日：2015-12-31

  The present invention provides quinoline derivatives of formula I that are PDE10A enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for PDE10 over other PDE subtypes. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

  本发明提供了式I的喹啉衍生物，它们是PDE10A酶抑制剂，因此可用于治疗神经退行性和精神障碍。特别地，本发明提供了高度选择性作用于PDE10而非其他PDE亚型的化合物。本发明还提供了包含本发明化合物的制药组合物和使用本发明化合物治疗疾病的方法。
• Substituted quinoxalines as PDE-10 inhibitors
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US10562916B2

  公开（公告）日：2020-02-18

  Provided herein are cyclic nucleotide phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

  本文提供了环核苷酸磷酸二酯酶抑制剂及其药物组合物，可用于治疗中枢神经系统和代谢疾病及紊乱等。
• Quinoline Derivatives as PDE10A Enzyme Inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20160303120A1

  公开（公告）日：2016-10-20

  The present invention provides quinoline derivatives of formula I that are PDE10A enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for PDE10A over other PDE subtypes. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.